Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Authors: Bo Lan, Yehui Shi, Xiying Shao, Fan Wu, Shusen Wang, Weimin Xie, Qingyuan Zhang, Quchang Ouyang, Jiuwei Cui, Xiaoling Ling, Haijun Yu, Huihui Li, Xianjun Tang, Sijuan Ding, Chunfang Hao, Bing Zhao, Yang Li, Hua Yang, Min Yan, Guohui Han, Xujuan Wang, Fanfan Li, Peijian Peng, Chang Gong, Yunjiang Liu, Junlan Guo, Yongmei Yin, Man Li, Yue’e Teng, Jiuda Zhao, Yongli Gao, Jingfen Wang, Jing Luo, Xinghua Han, Xiaoping Li, Bin Liu, Shuqun Zhang, Bihui Li, Lei Yang, Sa Xiao, Hai Zhu, Yi Zhu, Binghe Xu
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Zhejiang Cancer Hospital, Fujian Medical University, Fujian Provincial Cancer Hospital, Sun Yat-sen University Cancer Center, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Third Affiliated Hospital of Harbin Medical University, Hunan Cancer Hospital, First Hospital of Jilin University, First Hospital of Lanzhou University, Zhongnan Hospital of Wuhan University, Shandong First Medical University, Chongqing University, Chongqing Cancer Hospital, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University, First Affiliated Hospital of GuangXi Medical University, Affiliated Hospital of Hebei University, Henan Cancer Hospital, Shanxi Provincial Cancer Hospital, Second Affiliated Hospital of Anhui Medical University, Fifth Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Fourth Hospital of Hebei Medical University, Anyang Tumor Hospital, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, First Hospital of China Medical University, Qinghai University Affiliated Hospital, Linyi People's Hospital, Anhui Provincial Hospital, Jiangmen Central Hospital, Liaoning Cancer Hospital & Institute, Second Affiliated Hospital of Xi'an Jiaotong University, Guilin Medical University, Sichuan Baili Pharmaceutical Co., Ltd. (China)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7223678047